Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 12/20 | 0.43 |
| ▸ | ABL1 | P00519 | 7/20 | 0.43 |
| ▸ | RET | P07949 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.42 |
| ▸ | FYN | P06241 | 3/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | YES1 | P07947 | 2/20 | 0.42 |
| ▸ | LYN | P07948 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923676 | 0.81 | SRC (0.44) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3782929 | 0.74 | SRC (0.58) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL2592569 | 0.72 | KDM4E (0.33) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL409549 | 0.71 | SRC (0.47) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL15929311 | 0.71 | SRC (0.61) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10457496 | 0.69 | SRC (0.42) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL15471369 | 0.68 | SRC (0.58) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL22521563 | 0.68 | KDM4E (0.63) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13019650 | 0.67 | SRC (0.64) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3490944 | 0.66 | SRC (0.43) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021123798-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | MAP4K5, MAP4K4, MAP4K2 | KDM4E 673/4885ALDH1A1 2643/4885LMNA 3574/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | KDM4E 1558/4885ALDH1A1 4305/4885LMNA 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.